参考文献/References:
[1] Arbelo E,Protonotarios A,Gimeno JR,et al. 2023 ESC Guidelines for the management of cardiomyopathies[J]. Eur Heart J,2023,44(37):3503-3626.
[2] Ommen SR,Mital S,Burke MA,et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2020,142(25):e558-e631.
[3] Maron BJ. Clinical course and management of hypertrophic cardiomyopathy[J]. N Engl J Med,2018,379(7):655-668.
[4] Maron BJ,Desai MY,Nishimura RA,et al. Diagnosis and evaluation of hypertrophic?cardiomyopathy:JACC state-of-the-art review[J]. J Am Coll Cardiol ,2022,79(4):372-389.
[5] Kaple RK,Murphy RT,DiPaola LM,et al. Mitral valve abnormalities in hypertrophic cardiomyopathy:echocardiographic features and surgical outcomes[J]. Ann Thorac Surg,2008,85(5):1527-1535,1535.e1-e2.
[6] Patel P,Dhillon A,Popovic ZB,et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy:implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography[J]. Circ Cardiovasc Imaging,2015,8(7):e003132.
[7] 高一鸣. 肥厚型梗阻性心肌病二尖瓣器异常的超声心动图相关研究[D]. 北京：北京协和医学院,2021.
[8] Liu Y,Song Y,Gao G,et al. Outcomes of an extended Morrow procedure without a concomitant mitral valve procedure for hypertrophic obstructive cardiomyopathy[J]. Sci Rep,2016,6:29031.
[9] 国家心血管病中心心肌病专科联盟,中国医疗保健国际交流促进会心血管病精准医学分会,“中国成人肥厚型心肌病诊断与治疗指南2023”专家组. 中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国循环杂志,2023,38(1):1-33.
[10] Nagueh SF,Phelan D,Abraham T,et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy:an update from the American Society of Echocardiography,in collaboration with the American Society of Nuclear Cardiology,the Society for Cardiovascular Magnetic Resonance,and the Society of Cardiovascular Computed Tomography[J]. J Am Soc Echocardiogr,2022,35(6):533-569.
[11] Writing Committee Members,Ommen SR,Ho CY,et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy:A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2024,83(23):2324-2405.
[12] Ferrazzi P,Spirito P,Iacovoni A,et al. Transaortic chordal cutting:mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy[J]. J Am Coll Cardiol,2015,66(15):1687-1696.
[13] Hodges K,Rivas CG,Aguilera J,et al. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center[J]. J Thorac Cardiovasc Surg,2019,157(6):2289-2299.
[14] Maron MS,Olivotto I,Harrigan C,et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy[J]. Circulation,2011,124(1):40-47.
[15] Oliveira D,Srinivasan J,Espino D,et al. Geometric description for the anatomy of the mitral valve:a review[J]. J Anat,2020,237(2):209-224.
[16] Ferrazzi P,Spirito P,Binaco I,et al. Congenital muscular mitral-aortic discontinuity identified in patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2020,76(19):2238-2247.
[17] de Gaspari M,Mazzucato M,Bueno Marinas M,et al. Is Congenital Muscular Mitral-Aortic Discontinuity Another Feature of Obstructive Hypertrophic Cardiomyopathy? A Pathology Validation Study[J]. Lab Invest,2023,103(9):100196.
[18] 孟庆龙,王浩. 超声心动图评价二尖瓣-主动脉瓣联合体的价值与意义[J]. 中华超声影像学杂志,2019,28(5):453-457.
[19] Lentz Carvalho J,Schaff HV,Nishimura RA,et al. Is anterior mitral valve leaflet length important in outcome of septal myectomy for obstructive hypertrophic cardiomyopathy? [J]. J Thorac Cardiovasc Surg,2023,165(1):79-87.e1.
[20] Raffa GM,Romano G,Turrisi M,et al. Pathoanatomic findings and treatment during hypertrophic obstructive cardiomyopathy surgery:the role of mitral valve[J]. Heart Lung Circ,2019,28(3):477-485.
[21] Jain CC,Miranda WR,Geske JB,et al. Echocardiographic Characteristics of Severe Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy[J]. J Am Soc Echocardiogr,2021,34(7):798-801.
[22] Verheyen N,Batzner A,Zach D,et al. Spatial relationship between mitral valve and ventricular septum assessed by resting echocardiography to diagnose left ventricular outflow tract obstruction in hypertrophic cardiomyopathy[J]. ?Eur Heart J Cardiovasc Imaging,2023,24(6):710-718.
[23] Schwammenthal E,Nakatani S,He S,et al. Mechanism of mitral regurgitation in hypertrophic cardiomyopathy:mismatch of posterior to anterior leaflet length and mobility[J]. Circulation,1998,98(9):856-865.
[24] Gillinov AM,Cosgrove DM,Blackstone EH,et al. Durability of mitral valve repair for degenerative disease[J]. J Thorac Cardiovasc Surg,1998,116(5):734-743.
[25] Guigui SA,Torres C,Escolar E,et al. Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy:a narrative review[J]. J Thorac Dis,2022,14(6):2309-2325.
[26] Vainrib A,Massera D,Sherrid MV,et al. Three-dimensional imaging and dynamic modeling of systolic anterior motion of the mitral valve[J]. J Am Soc Echocardiogr,2021,34(1):89-96.
[27] Silbiger JJ. Abnormalities of the mitral apparatus in hypertrophic cardiomyopathy:echocardiographic,pathophysiologic,and surgical insights[J]. J Am Soc Echocardiogr,2016,29(7):622-639.
[28] Hang D,Schaff HV,Nishimura RA,et al. Accuracy of jet direction on Doppler echocardiography in identifying the etiology of mitral regurgitation in obstructive hypertrophic cardiomyopathy[J]. J Am Soc Echocardiogr,2019,32(3):333-340.
[29] Lomholt M,Nielsen SL,Hansen SB,et al. Differential tension between secondary and primary mitral chordae in an acute in-vivo porcine model[J]. J Heart Valve Dis,2002,11(3):337-345.
[30] Rodriguez F,Langer F,Harrington KB,et al. Importance of mitral valve second-order chordae for left ventricular geometry,wall thickening mechanics,and global systolic function[J]. Circulation,2004,110(11 suppl 1):Ⅱ-115-Ⅱ-122.
[31] Klues HG,Maron BJ,Dollar AL,et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy[J]. Circulation,1992,85(5):1651-1660.
[32] Schaff HV,Said SM. Transaortic extended septal myectomy for hypertrophic cardiomyopathy[J]. Oper Tech Thorac Cardiovasc Surg,2012,17(4):238-250.
[33] Wang S,Cui H,Yu Q,et al. Excision of anomalous muscle bundles as an important addition to extended septal myectomy for treatment of left ventricular outflow tract obstruction[J]. J Thorac Cardiovasc Surg,2016,152(2):461-468.
[34] Minakata K,Dearani JA,Nishimura RA,et al. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae[J]. J Thorac Cardiovasc Surg,2004,127(2):481-489.
[35] Madu EC,D’Cruz IA. The vital role of papillary muscles in mitral and ventricular function:echocardiographic insights[J]. Clin Cardiol,1997,20(2):93-98.
[36] Uemura T,Otsuji Y,Nakashiki K,et al. Papillary muscle dysfunction attenuates ischemic mitral regurgitation in patients with localized basal inferior left ventricular remodeling:insights from tissue Doppler strain imaging[J]. J Am Coll Cardiol,2005,46(1):113-119.
[37] Kobashi A,Suwa M,Ito T,et al. Solitary papillary muscle hypertrophy as a possible form of hypertrophic cardiomyopathy[J]. Jpn Circ J,1998,62(11):811-816.
[38] Tischler MD,Rothfeld J. Papillary muscle fractional shortening is a determinant of heart shape in patients with prior myocardial infarction[J]. Am J Cardiol,1997,80(2):204-206.
[39] Harrigan CJ,Appelbaum E,Maron BJ,et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy[J]. Am J Cardi,2008,101(5):668-673.
[40] Cavalcante JL,Barboza JS,Lever HM. Diversity of mitral valve abnormalities in obstructive hypertrophic cardiomyopathy[J]. Prog Cardiovasc Dis,2012,54(6):517-522.
[41] Kwon DH,Setser RM,Thamilarasan M,et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy[J]. Heart,2008,94(10):1295-1301.
[42] Klues HG,Roberts WC,Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction[J]. Circulation,1991,84(3):1188-1197.
[43] Lentz Carvalho J,Schaff HV,Morris CS,et al. Anomalous papillary muscles—Implications in the surgical treatment of hypertrophic obstructive cardiomyopathy[J]. Thorac Cardiovasc Surg,2022,163(1):83-89.e1.
[44] Levine RA,Vlahakes GJ,Lefebvre X,et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction[J]. Circulation,1995,91(4):1189-1195.
[45] Kim DH,Handschumacher MD,Levine RA,et al. In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy[J]. Circulation,2010,122(13):1298-1307.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(11):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(11):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(11):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[4]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(11):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[5]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[6]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[7]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(11):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[8]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[9]李传伟,罗浩,曾春雨.肥厚型心肌病室间隔消减策略的研究进展[J].心血管病学进展,2022,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
LI Chuanwei,LUO Hao,ZENG Chunyu.Septal Reduction Therapy of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(11):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
[10]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(11):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]